MediWound Ltd. (MDWD)
NASDAQ: MDWD · IEX Real-Time Price · USD
18.24
+0.58 (3.28%)
Apr 26, 2024, 4:30 PM EDT - Market closed
MediWound Revenue
In the year 2023, MediWound had annual revenue of $18.69M, a decrease of -29.48%. Revenue in the quarter ending December 31, 2023 was $5.34M, a -54.05% decrease year-over-year.
Revenue (ttm)
$18.69M
Revenue Growth
-29.48%
P/S Ratio
9.27
Revenue / Employee
$186,860
Employees
100
Market Cap
173.13M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 18.69M | -7.81M | -29.48% |
Dec 31, 2022 | 26.50M | 2.73M | 11.50% |
Dec 31, 2021 | 23.76M | 2.00M | 9.19% |
Dec 31, 2020 | 21.76M | -10.03M | -31.54% |
Dec 31, 2019 | 31.79M | 28.39M | 834.70% |
Dec 31, 2018 | 3.40M | 905.00K | 36.26% |
Dec 31, 2017 | 2.50M | 938.00K | 60.21% |
Dec 31, 2016 | 1.56M | 957.00K | 159.23% |
Dec 31, 2015 | 601.00K | 342.00K | 132.05% |
Dec 31, 2014 | 259.00K | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 0 | - | - |
Dec 31, 2011 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
InfuSystem Holdings | 125.79M |
The Joint | 117.70M |
Genfit | 42.42M |
Compugen | 33.46M |
Inventiva | 25.74M |
Capricor Therapeutics | 25.18M |
bluebird bio | 21.73M |
MDWD News
- 1 day ago - MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences - GlobeNewsWire
- 5 weeks ago - MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update - GlobeNewsWire
- 6 weeks ago - MediWound to Report Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire
- 2 months ago - MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study - GlobeNewsWire
- 2 months ago - MediWound to Participate in Two Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns - GlobeNewsWire
- 4 months ago - MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army - GlobeNewsWire
- 4 months ago - MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads - GlobeNewsWire